| Product Code: ETC13176705 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Vaccines Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Vaccines Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Vaccines Market Revenues & Volume, 2021 & 2031F |
3.3 North America Vaccines Market - Industry Life Cycle |
3.4 North America Vaccines Market - Porter's Five Forces |
3.5 North America Vaccines Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Vaccines Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 North America Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 North America Vaccines Market Revenues & Volume Share, By Disease Indication, 2021 & 2031F |
3.9 North America Vaccines Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 North America Vaccines Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
4 North America Vaccines Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Vaccines Market Trends |
6 North America Vaccines Market, 2021 - 2031 |
6.1 North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Vaccines Market, Revenues & Volume, By Conjugate vaccines, 2021 - 2031 |
6.1.3 North America Vaccines Market, Revenues & Volume, By Inactivated and subunit vaccines, 2021 - 2031 |
6.1.4 North America Vaccines Market, Revenues & Volume, By Live attenuated vaccines, 2021 - 2031 |
6.1.5 North America Vaccines Market, Revenues & Volume, By Recombinant vaccines, 2021 - 2031 |
6.1.6 North America Vaccines Market, Revenues & Volume, By Toxoid vaccines, 2021 - 2031 |
6.2 North America Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Vaccines Market, Revenues & Volume, By Monovalent vaccines, 2021 - 2031 |
6.2.3 North America Vaccines Market, Revenues & Volume, By Multivalent vaccines, 2021 - 2031 |
6.3 North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Vaccines Market, Revenues & Volume, By Pneumococcal disease, 2021 - 2031 |
6.3.3 North America Vaccines Market, Revenues & Volume, By DTP, 2021 - 2031 |
6.3.4 North America Vaccines Market, Revenues & Volume, By Influenza, 2021 - 2031 |
6.3.5 North America Vaccines Market, Revenues & Volume, By HPV, 2021 - 2031 |
6.3.6 North America Vaccines Market, Revenues & Volume, By Meningococcal disease, 2021 - 2031 |
6.3.7 North America Vaccines Market, Revenues & Volume, By Polio, 2021 - 2031 |
6.3.8 North America Vaccines Market, Revenues & Volume, By Rotavirus, 2021 - 2031 |
6.3.9 North America Vaccines Market, Revenues & Volume, By Other disease indications, 2021 - 2031 |
6.4 North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.4.2 North America Vaccines Market, Revenues & Volume, By Intramuscular and subcutaneous administration, 2021 - 2031 |
6.4.3 North America Vaccines Market, Revenues & Volume, By Oral administration, 2021 - 2031 |
6.4.4 North America Vaccines Market, Revenues & Volume, By Other routes of administration, 2021 - 2031 |
6.5 North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 North America Vaccines Market, Revenues & Volume, By Pediatric patients, 2021 - 2031 |
6.5.3 North America Vaccines Market, Revenues & Volume, By Adult patients, 2021 - 2031 |
7 North America Vaccines Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.1 United States (US) Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.2 Canada Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.2.3 Rest of North America Vaccines Market, Revenues & Volume, By Technology, 2021 - 2031 |
7.3 North America Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F |
7.3.1 United States (US) Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3.2 Canada Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3.3 Rest of North America Vaccines Market, Revenues & Volume, By Type, 2021 - 2031 |
7.4 North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.1 United States (US) Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.2 Canada Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.4.3 Rest of North America Vaccines Market, Revenues & Volume, By Disease Indication, 2021 - 2031 |
7.5 North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.1 United States (US) Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.2 Canada Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5.3 Rest of North America Vaccines Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.1 United States (US) Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.2 Canada Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
7.6.3 Rest of North America Vaccines Market, Revenues & Volume, By Patient Type, 2021 - 2031 |
8 North America Vaccines Market Key Performance Indicators |
9 North America Vaccines Market - Export/Import By Countries Assessment |
10 North America Vaccines Market - Opportunity Assessment |
10.1 North America Vaccines Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Vaccines Market Opportunity Assessment, By Technology, 2021 & 2031F |
10.3 North America Vaccines Market Opportunity Assessment, By Type, 2021 & 2031F |
10.4 North America Vaccines Market Opportunity Assessment, By Disease Indication, 2021 & 2031F |
10.5 North America Vaccines Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10.6 North America Vaccines Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
11 North America Vaccines Market - Competitive Landscape |
11.1 North America Vaccines Market Revenue Share, By Companies, 2022 |
11.2 North America Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here